Differences in pre-pandemic mother-daughter relationships, and social and adaptive behavior significantly predicted worries and impact of the COVID-19 pandemic in school-aged girls with fragile X syndrome (FXS), a U.S. study reports. Notably, this association pattern was distinct from that of matched girls without the condition, whose responses were determined…
News
Nova Mentis, a Canadian biotechnology company, is teaming up with KGK Science to develop Nova’s portfolio of therapies based on the psychedelic compound psilocybin. The companies are planning to ask Health Canada for the go-ahead to launch a Phase 2 clinical trial in fragile X syndrome that would test…
The ABLE Employment Flexibility Act and better workplace opportunities for people with disabilities are among priorities for this year’s National Fragile X Foundation (NFXF) Advocacy Day, set for March 1. For more than 20 years, the nonprofit organization has brought advocates together in Washington, D.C., to meet…
Gene therapy rescued several behavioral and brainwave abnormalities seen in a rat model of fragile X syndrome. Findings from the study support further development of gene therapy for treating people people with the condition, the scientists said. The study, “Gene Therapy Using an Orthologue of Human…
Nova Mentis and Mycrodose Therapeutics have teamed up to test whether psychedelic treatments, such as Nova’s psilocybin — a potential behavioral therapy for fragile X syndrome — can be delivered via the skin using Mycrodose’s transdermal technology. The first studies assessing the diffusion of psychedelic compounds through the…
Zygel, an experimental cannabidiol gel that Zynerba Pharmaceuticals is developing to help normalize behaviors in people with fragile X syndrome, continues to be well tolerated up to a median treatment length of 21 months, according to new data from the open-label extension of the Phase 2/3 CONNECT-FX trial.
To help find new fragile X treatments, the Robert & Ardis James Foundation has presented the Fraxa Research Foundation with a donor-matching challenge of up to $100,000. All funds raised will go toward research to develop therapies, and ultimately a cure, for fragile X, a genetic condition associated…
Wearable motion sensors someday may help doctors diagnose fragile X syndrome and similar disorders based on the way people walk, a study suggests. The method may be able to identify problems in walking 15 to 20 years ahead of clinical symptoms; as such, it offers an opportunity to intervene sooner to…
A five-year, $2.4 million grant will fund a new study of grammar skills and executive functions in preschool and school-age children with fragile X syndrome. The grant, awarded by National Institute on Deafness and Other Communication Disorders, part of the National Institutes of Health, will be…
A candidate therapy for fragile X syndrome — developed using Quris’ bio-artificial intelligence clinical prediction platform — will enter clinical trials in 2022, the company announced. Quris is using the power of artificial intelligence (AI) combined with a “patients-on-a-chip” platform to predict the safety and potential effectiveness of therapeutic…
Recent Posts
- Study highlights demands of caregiving in fragile X syndrome
- Experimental therapy improves behavior, cognition in fragile X mice
- Advocates aim to answer the question ‘Fragile what?’ this awareness month
- Fragile X drug zatolmilast misses main goal in Phase 3 trials
- Targeting star-shaped brain cells reduces fragile X seizures in mice: Study
- Marvel planning trial to test fragile X treatment in healthy volunteers
- FRAXA backs upcoming Phase 2b trial of SPG601 for fragile X syndrome
- Daily use of diabetes drug metformin eases hyperactivity in fragile X boys
- USC researchers net $6.3M federal grant to study fragile X mutations
- 1st patient enrolled in Phase 2 trial of treatment for fragile X syndrome